Chapter 7 248 39. Ricciuti, B. et al. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J. Thorac. Oncol. 17, 399–410 (2022). 40. Zhao, Y. et al. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy. Immunology 164, 507–523 (2021). 41. Weide, B. et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin. Cancer Res. 20, 1601–1609 (2014). 42. Kim, H. J. & Cantor, H. CD4 T-cell subsets and tumor immunity: the helpful and the notso-helpful. Cancer Immunol. Res. 2, 91–98 (2014). 43. Hou, A., Hou, K., Huang, Q., Lei, Y. & Chen, W. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. Front. Immunol. 11, 1–19 (2020). 44. Koelzer, V. H. et al. Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma. Histopathology 73, 397–406 (2018). 45. Ebert, M. P. et al. Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. Lancet Heal. Longev. 3, e417–e427 (2022). 46. Ghaffari Laleh, N., Ligero, M., Perez-Lopez, R. & Kather, J. N. Facts and Hopes on the Use of Artificial Intelligence for Predictive Immunotherapy Biomarkers in Cancer. Clin. Cancer Res. 29, 316–323 (2023). 47. Veldman-Jones, M. H. et al. Evaluating robustness and sensitivity of the nanostring technologies ncounter platform to enable multiplexed gene expression analysis of clinical samples. Cancer Res. 75, 2587–2593 (2015). 48. Geiss, G. K. et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26, 317–325 (2008). 49. Wallden, B. et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med. Genomics 8, 1–14 (2015). 50. Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499 (2015). 51. Liu, B., Zhang, Y., Wang, D., Hu, X. & Zhang, Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13 + T cells to immune-checkpoint blockade. Nat. Cancer 3, 1123–1136 (2022). 52. Xia, A., Zhang, Y., Xu, J., Yin, T. & Lu, X. J. T Cell Dysfunction in Cancer Immunity and Immunotherapy. Front. Immunol. 10, 1719 (2019). 53. van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218–232 (2020). 54. Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018). 55. Paz-Ares, L. et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. N. Engl. J. Med. 379, 2040–2051 (2018). 56. Reck, M. et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N. Engl. J. Med. 375, 1823–1833 (2016). 57. Wang, D. Y. et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 4, 1721–1728 (2018).
RkJQdWJsaXNoZXIy MTk4NDMw